Update: The coming into force date of the amended Patented Medicines Regulations has been deferred, once again, until July 1, 2022, which as announced on April 14, 2022, will be released in a substantially amended form.
Further to our last update on the amendments to the Patented Medicines Regulations (see
here) and related Guidance (see
here), the Patented Medicine Prices Review Board (PMPRB) has today
announced
that:
- The coming into force date of the amended Patented Medicines Regulations will now be January 1, 2021; and
- A revised set of draft Guidelines will be published the week of June 15, 2020 followed by a 30-day consultation period.
The most immediate and practical impact of this change is that reporting requirements due by July 30, 2020 of sales and pricing information for the period from January 1, 2020 to June 30, 2020 will clearly be governed by the current Regulations (see our later article here).
Related Publications & Articles
-
CDA update: new five-year strategic plan and position statement on using AI in health technology assessments
On April 15, 2025 Canada’s Drug Agency (CDA) released its new five-year strategic plan, Insight to Impact 2025-2030.Read More -
Updated PMPRB Guidelines expected in summer 2025 and NPDUIS releases ninth edition of the Meds Entry Watch Report
In the Patented Medicine Prices Review Board (PMPRB)’s June 2025 NEWSletter, Acting Chairperson Anie Perrault confirms that the PMPRB plans on publishing its final Guidelines in summer 2025.Read More -
Update on biosimilars in Canada – June 2025
This article provides an update on developments in the biosimilar space in Canada—regulatory, approvals, pending submissions, litigation, and market access.Read More